期刊文献+

RP-HPLC法测定阿哌沙班片的含量及有关物质 被引量:9

Determination the Content and Related Substances of Apixaban Tablets by RP-HPLC
原文传递
导出
摘要 目的:建立测定阿哌沙班片的含量及有关物质的方法。方法:采用反相高效液相色谱法。色谱柱为Waters XBridge Shield RP18柱,流动相为乙腈-0.05 mol/L磷酸二氢钾溶液(用50%磷酸溶液调节p H至3.0)(20∶80,V/V),流速为1.0 ml/min,检测波长为293 nm,柱温为25℃,进样量为10μl。结果:在所建立的色谱条件下,阿哌沙班与各杂质及其降解产物分离良好;阿哌沙班的质量浓度在4.30~45.00μg/ml范围内与峰面积积分值呈良好的线性关系(r=0.999 4);精密度、稳定性、重复性试验的RSD≤1.10%;阿哌沙班的平均加样回收率为99.93%,RSD为0.30%(n=3);其最大单个杂质的质量分数为0.019%~0.026%,总杂质的质量分数为0.062%~0.074%。结论:本方法操作简便、结果准确、灵敏度高,适用于阿哌沙班片的含量及有关物质测定,对建立阿哌沙班片的质量控制标准有一定的参考价值。 OBJECTIVE: To establish a method for the determination of content and related substances of Apixaban tablets. METHODS : RP-HPLC was adopted with Water XBridge Shield RP18 column, the mobile phase was acetonitrile -0.05 mol/L potas- sium dihydrogen phosphate solution (adjusted with 50% phosphoric acid to pH 3.0)(20:80, V/V) with flow velocity of 1.0 ml/min. Detection wavelength was set at 293 nm, the column temperature was 25 ℃, the injection volume was 10 μl. RESULTS: Under the establishment of chromatographic conditions, apixaban impurities and its degradation products had a good degree of separation; there was a good linear relationship between the content of apixaban in the range of 4.30 - 45.00 μg/ml and peak area values (r= 0.999 4). The RSD of precision, stability, repeatability tests were no more than 1.10%, the average recovery of apixaban was 99.93%, RSD was 0.30% (n=3). The largest single impurity content in mass fraction was in the range of 0.019% to 0.026%, the total impurity content in mass fraction was 0.062% to 0.074%. CONCLUSIONS: The method is simple, accurate, sensitive and can be used to determine the content and related substances of Apixaban tablets. It provides reference for the establishment of the quality control standard of Apixaban tablets.
作者 武少馨 李丹
出处 《中国药房》 CAS 北大核心 2015年第6期828-831,共4页 China Pharmacy
关键词 阿哌沙班片 反向高效液相色谱法 含量 有关物质 质量控制 Apixaban tablets RP-HPLC Content Related substances Quality control
  • 相关文献

参考文献8

二级参考文献60

  • 1冀亚飞,蒋健安,刘倩,等.一种抗血栓药物阿匹沙班的制备方法:中国,101967145[P].2010-09-09.
  • 2Friedman RJ,Dahl OE,Rosencher N,et al.Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty:a pooled analysis of three trials[J].Thromb Res,2010,126(3):175-182.
  • 3Eriksson BI,Dahl OE,Huo MH,et al.Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*)[J].Thromb Haemost,2011,105(4):721-729.
  • 4Schulman S,Kearon C,Kakkar AK,et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J].N Engl J Med,2009,361(24):2342-2352.
  • 5Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
  • 6Wann LS,Curtis AB,Ellenbogen KA,et al.2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran):a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2011,123(10):1144-1150.
  • 7Oldgren J,Budaj A,Granger CB,et al.Dabigatran vs.placebo in patients with acute coronary syndromes on dual antiplatelet therapy:a randomized,double-blind,phase II trial[J].Eur Heart J,2011,32(22):2781-2789.
  • 8Eriksson BI,Borris LC,Friedman RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,358(26):2765-2775.
  • 9Kakkar AK,Brenner B,Dahl OE,et al.Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind,randomised controlled trial[J].Lancet,2008,372(9632):31-39.
  • 10Lassen MR,Ageno W,Borris LC,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med,2008,358(26):2776-2786.

共引文献62

同被引文献55

引证文献9

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部